TNFRSF17 and plasma cell myeloma: CAR T-cells are under development to target many forms of cancer, with the best clinical results demonstrated thus far against hematological disorders, such as B-cell leukemia and lymphoma through the targeting of the lineage-restricted B-cell molecule CD19 and multiple myeloma by targeting B-cell maturation antigen (BCMA).